Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke

Cerebrovascular Diseases

Volumn 8, Issue 3, 1998, Pages 172-181

  Diener, Hans Christoph ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Efficacy; Ischaemic stroke; Lubeluzole; Safety

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; LUBELUZOLE;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LONG QT SYNDROME; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PIPERIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 0031923952     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000015847     Document Type: Article

References (22)

1. Annual World Health Statistics. Geneva, World Health Organization, 1992.
2. Bots ML, Looman SJ, Koudstaal PJ, Hofman A, Hoes AW, Grobbee DE: Prevalence of stroke in the general population: The Rotterdam Study. Stroke 1996;27:1499-1501.
3. Khaw K-T: Epidemiology of stroke. J Neurol Neurosurg Psychiatry 1996;61:333-338.
4. Reith J. Jörgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Jeppesen LL, Skyhöj Olsen T: Body temperature in stroke: Relation to stroke severity, infarct size, mortality and outcome. Lancet 1996;347:422-425.
5. Nakayama H, Jörgensen HS, Raashou HO, et al: The influence of age on stroke outcome. The Copenhagen Stroke Study. Stroke 1994;25: 808-813.
6. Westling B, Norrving B, Thorngren M: Survival following stroke: A prospective population-based study of 438 hospitalized cases with prediction according to subtype, severity and age. Acta Neurol Scand 1990;81:457-463.
7. DeRyck M, Keersmackers R, Duytschaever H, Claes C, Clincke G, Janssen M, et al: Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J Pharmacol Exp Ther 1996;279: 748-758.
8. Aronowski J, Strong R, Grotta JC: Treatment of experimental foci ischemia in rats with lubeluzole. Neuropharmacology 1996;35:689-693.
9. Scheller D, Kolb J, Szathmary S, Zacharias E, DeRyck M, Van Reempts J, Clincke B, Tegtmeier F: Extracellular changes of glutamate in the periinfarct zone: Effect of lubeluzole. J Cereb Blood Flow Metab 1995;15(suppl 1):S379.
10. Buchkremer-Ratzmann I, Witte OW: Periinfarct and transhemispheric diaschisis caused by photothrombotic infarction in rat neocortex is reduced by lubeluzole but not MK-801 (abstract). J Cereb Blood Flow Metab 1995; 15(suppl 1):S38.
11. Lesage AS, Peeters L, Leysen JF: Lubeluzole, a novel long-term neuroprotectant, inhibits the glutamate-activated nitric oxide synthetase pathway. J Pharmacol Exp Ther 1996;279: 759-766.
12. Maiese K, Tenbroeke M, Kue I: Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide. J Neurochem 1997;68:710-714.
13. Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, DeKeyser J, et al, for the Lubeluzole International Study Group: Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Stroke 1996;27:76-81.
14. Grotta J, for the US and Canadian Lubeluzole Ischemic Stroke Study Group: Lubeluzole treatment of acute ischemic stroke. Stroke 1997;28:2338-2346.
15. Hantson L, De Weerdt W, De Keyser J, Diener HC, Franke C, Palm R, et al: The European Stroke Scale. Stroke 1994;25:2215-2219.
16. Mahoney FI, Barthel DW: Functional evaluation: The Barthel Index. Md State Med J 1965; 14:61-65.
17. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
18. Hacke W, Hennerici H, Hantson L, Diener HC: Lubeluzole - A new neuroprotectant agent in the treatment of acute ischemic stroke: Results of a cardiovascular safety study in stroke patients (abstract). Neurology 1996;46:A429.
19. Lyden P, for the NINDS Treatment Group: Generalised efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA stroke trial by the NINDS rt-PA stroke study group (abstract). 22nd International Joint Conference on Stroke and Cerebral Circulation. Anaheim, 1997.
20. Anderson C: Baseline measures and outcome predictions. Neuroepidemiology 1994;13:283-289.
21. Davis S, Albers GW, Diener HC, Lees KR, Norris J: Termination of acute stroke studies involving selfotel treatment. Lancet 1997;349: 32.
22. Wahlgren NG: Neuroprotectants in late clinical development - A status report. Cerebrovasc Dis 1997;7(suppl 2):13-17.